Who
Matthew L. Posard
Director
Company insider
Files Form 4 as: Director, Halozyme Therapeutics; Director, Nautilus Biotechnology; Director, Talis Biomedical; Director, DermTech; Chief Commercial Officer, Cardiff Oncology; Sr VP & General Manager, Illumina.
In numbers
- Trades disclosed
- 99
- Buys
- 4
- Sells
- 12
- Bought
- $2.2M
- Sold
- $12.1M
- Companies
- 6
- Companies where not an officer
- 4
- First trade
- 8 Mar 2012
- Last trade
- 1 Oct 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 2 Oct 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Sold | $78K730 at $107.17 | filing |
| 1 Oct 2026filed 2 Oct 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Sold | $358K3,300 at $108.45 | filing |
| 1 Oct 2026filed 2 Oct 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Sold | $121K1,100 at $109.57 | filing |
| 1 Oct 2026filed 2 Oct 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Sold | $11K100 at $110.04 | filing |
| 16 Sep 2026filed 17 Sep 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Sold | $329K3,100 at $106.13 | filing |
| 16 Sep 2026filed 17 Sep 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Sold | $320K3,000 at $106.83 | filing |
| 16 Sep 2026filed 17 Sep 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Sold | $961K8,896 at $108.04 | filing |
| 16 Sep 2026filed 17 Sep 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Sold | $436K4,000 at $108.99 | filing |
| 16 Sep 2026filed 17 Sep 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Sold | $329K3,100 at $106.13 | filing |
| 16 Sep 2026filed 17 Sep 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Sold | $320K3,000 at $106.83 | filing |
| 16 Sep 2026filed 17 Sep 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Sold | $961K8,896 at $108.04 | filing |
| 16 Sep 2026filed 17 Sep 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Sold | $436K4,000 at $108.99 | filing |
| 18 Jun 2026filed 22 Jun 2026 | NAUT Nautilus Biotechnologyoption or derivative · Life-science tools | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 18 Jun 2026filed 22 Jun 2026 | NAUT Nautilus Biotechnologyoption or derivative · Life-science tools | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 5 May 2026filed 7 May 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Code A | —3,796 at $0.00 | filing |
| 5 May 2026filed 7 May 2026 | HALO Halozyme Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,040 at $0.00 | filing |
| 5 May 2026filed 7 May 2026 | HALO Halozyme Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,040 at $0.00 | filing |
| 5 May 2026filed 7 May 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Code A | —3,796 at $0.00 | filing |
| 23 Jun 2025filed 25 Jun 2025 | NAUT Nautilus Biotechnologyoption or derivative · Life-science tools | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 1 May 2025filed 2 May 2025 | HALO Halozyme Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,750 at $0.00 | filing |
News
Halozyme Therapeutics (NASDAQ:HALO) CEO Sells $2,188,000.00 in StockHALO · themarketsdaily.com · 9 Oct 2026Halozyme Therapeutics (NASDAQ:HALO) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst SaysHALO · tickerreport.com · 8 Oct 2026
0 headlines in the last 90 days name Matthew L. Posard; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.